ALC vs RMD
Alcon Inc. and ResMed, both Healthcare
Alcon Inc. is the larger company at $33B against $27B. On trailing earnings RMD is the cheaper of the two at a P/E of 22.1 against 48.2, a gap that is only a bargain if the two are growing at similar rates. Over the past year RMD returned -15% against -17% for ALC. The RyuScore puts RMD ahead, 83 against 51 out of 100.
| Figure | ALC | RMD |
|---|---|---|
| Last close | $64.11 | $230 |
| Market cap | $33B | $27B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 48.2 | 22.1 |
| Dividend yield | n/a | 1.0% |
| 1-year return | -17% | -15% |
| 5-year return | -25% | -17% |
| RyuScoresector-relative, 1–10 | 51/100 | 83/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Alcon Inc.
Revenue of $5.3B in H2 2025, net income $454M.
ResMed
Revenue of $1.5B in Q4 2026, net income $383M. Its largest reported line is Sleep And Breathing Health, 88% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.